Registration Options

Activity Dates: 02/26/2021 - 11/30/2021

Members can access this product for only $160. Log in or Join now!

Target Audience

This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.

Content

The articles selected by CPNP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Patient Management, Domain 2: Information Management, Domain 3: Health Policy and Practice Management.

The Literature Analysis is a self-study, online only, application-based continuing pharmacy education (CPE) activity. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. The Literature Analysis includes:

  • Electronic access to all required journal articles needed to prepare for the online assessment.
  • For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination.
  • Access to the CPNP testing center with exam submission due by or on November 30, 2021.

Course Requirements

To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the recertification education.
  2. Complete an online assessment on or before the deadline of November 30, 2021.
  3. Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
  4. Partial credit is not available for individual topics within the Literature Analysis programming; it is either all 10 hours of Literature Analysis programming credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (66%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor.

Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.

Learning Objectives

Article Number Topic Article and Learning Objectives
1 Trends in Psychotropic Med Use

Keast SL, Tidmore LM, Shropshire D, et al. Characterization of chronic multiclass psychotropic polypharmacy and psychotherapy in foster care youth in a state medicaid population. J Manag Care Spec Pharm. 2019;25(12):1340-1348.

  1. Assess patterns of psychotropic medication use in foster care youth.
  2. Provide rationale for systems and quality measures to improve psychotropic medication prescribing in foster care youth.
  3. Develop policies to optimize the treatment and monitoring of mental health conditions in foster care youth.
2 Applicability and Generalizability of Research Findings

Susukida, R, Crum, RM, Hong, H, Stuart, EA, Mojtabai, R. Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta‐analytic studies. Int J Methods Psychiatr Res. 2018; 27:e1609. https://doi.org/10.1002/mpr.1609

  1. Evaluate study design limitations of randomized controlled trials and meta-analyses assessing pharmacologic treatment for cocaine dependence.
  2. Assess the generalizability of randomized controlled trials on pharmacologic interventions to treat cocaine dependence.
  3. Propose study design strategies to enhance the generalizability of cocaine dependence studies.
3 Child/Adolescent

Ray WA, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162-171.

  1. Evaluate the impact on cardiovascular outcomes associated with antipsychotic use in the pediatric population.
  2. Assess dose-related effects on mortality when antipsychotics are prescribed for the pediatric population.
  3. Compare differences in mortality between antipsychotics and other psychotropic agents in children and adolescents.
4 Study Design

Edmond SN, et al. Considerations of trial design and conduct in behavioral interventions for the management of chronic pain in adults. Pain Reports. 2019;4(e655):1-10.

  1. Develop study methods that reflect considerations unique to a behavioral intervention study.
  2. Modify outcomes of a behavioral intervention study to include clinically relevant pain domains.
  3. Employ strategies to increase the treatment fidelity of a behavioral intervention study.
5 Ethical Issues

Palmer BW, et al. Determinants of capacity to consent to research on Alzheimer's disease. Clin Gerontol. 2017; 40(1): 24-34.

  1. Evaluate the impact patient characteristics have on the capacity to provide consent for research in patients diagnosed with mild-to-moderate Alzheimer’s disease.
  2. Educate patients and/or caregivers on the capacity for patients diagnosed with mild-to-moderate Alzheimer’s disease to provide consent for research.
  3. Develop a quality improvement project protocol to include determination of capacity to consent for patient’s diagnosed with mild-to-moderate Alzheimer’s disease.
6 Nicotine

Siegel DA, et al. Update: Interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury - United States, October 2019.

  1. Recommend appropriate medical workup for evaluation of suspected EVALI.
  2. Develop a treatment plan for suspected EVALI.
  3. Propose public health recommendations to mitigate the risk of EVALI.
7 Health Literacy

Vovou F, et al. Mental health literacy of ADHD, autism, schizophrenia, and bipolar disorder: a cross-cultural investigation. J Ment Health 2020 Jan 29;1-11. doi: 10.1080/09638237.2020.1713999.

  1. Interpret cultural and sociodemographic data in relation to mental health literacy.
  2. Educate healthcare professionals on factors that influence mental health literacy.
  3. Evaluate the impact of the limitations of this study on the generalizability of the results.
8 Adverse Effects of Antidepressants

Miidera H et al. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes: A Large, Population-Based Cohort Study in Japan. Diabetes Care 2020 Apr; 43(4): 885-893.

  1. Characterize the association of new onset type 2 diabetes with antidepressant use.
  2. Differentiate risk factors for the development of antidepressant-related type 2 diabetes.
  3. Develop a therapeutic treatment plan for patients with or at risk for antidepressant-related type 2 diabetes.
9 Halmark Trial

Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–318.

  1. Analyze the X:BOT study design, limitations, and/or results in order to provide evidence-based recommendations.
  2. Educate providers on the landmark clinical trial, X:BOT, for application in clinical practice.
  3. Develop a quality improvement plan to optimize the treatment of opioid use disorder.
10 Mood Disorders

Kaster, T.S., Daskalakis, Z.J., Noda, Y. et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacol 43, 2231–2238 (2018). https://doi.org/10.1038/s41386-018-0121-x

  1. Evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in late-life depression.
  2. Analyze patient-specific characteristics that may impact the safety and/or efficacy of deep repetitive transcranial magnetic stimulation (rTMS).
  3. Assess the potential risks of deep repetitive transcranial magnetic stimulation (rTMS) in late-life depression.

Continuing Education Credit and Disclosures

Activity Dates: 02/26/2021 - 11/30/2021
ACPE Contact Hours: 10
ACPE Number: 0284-0000-21-030-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.